BRISTOL MYERS SQUIBB

In 2024, the FDA approved 34 new drugs, including treatments like Bristol Myers Squibb's Cobenfy, Eli Lilly's Kisunla, and Merck's Winrevair. In 2025, expect more breakthroughs, such as a non-opioid pain medication and a long-acting HIV prevention treatment.

The global biotechnology market is projected to grow from US$ 550.83 billion in 2024 to US$ 2667.36 billion by 2034, driven by advancements in synthetic biology, CRISPR gene editing, and genomic sequencing. Increasing health issues and genetic abnormalities are boosting demand for biopharmaceuticals. North America leads in market share, while India's agricultural biotechnology sector is rapidly expanding.

Adjuvant atezolizumab and nivolumab showed no significant DFS or OS improvement in RCC post-nephrectomy, while pembrolizumab significantly improved DFS and OS. Ongoing trials with durvalumab and belzutifan plus pembrolizumab aim to further enhance survival outcomes in RCC.

Be Biopharma raised $82m to advance hemophilia B gene therapy BE-101 to Phase I/II trial, adding ex-Roche exec Suha Patel. BE-101, an FDA-approved gene therapy, aims to provide durable FIX replacement for hemophilia B patients.

Redwire partners with Bristol Myers Squibb to study small molecule drug compounds on ISS, enhancing drug stability and manufacturing efficiency. Additionally, Redwire collaborates with ExesaLibero Pharma to investigate bone disease treatments in space, launching 12 more PIL-BOXes on the next ISS mission.

Cobenfy, a new schizophrenia treatment by Bristol Myers Squibb, targets muscarinic receptors instead of dopamine, offering an alternative to traditional treatments with severe side effects.

FDA approved Cobenfy, a novel schizophrenia drug combining xanomeline and trospium chloride, targeting cholinergic receptors instead of dopamine. Schizophrenia, affecting 1 in 100, has serious consequences including social isolation and a 13-15 year reduced life expectancy. Cobenfy aims to avoid older drugs' side-effects, though it has its own side-effects like nausea and dizziness, priced at $1,850 a month.

The gene therapy market is rapidly expanding, with over 180 companies developing more than 200 gene therapies. Key players include Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, and Adverum Biotechnologies. Prominent therapies in the pipeline include DTX401, RP-L102, and ADVM-022. Gene therapy aims to treat diseases by modifying genes, offering potential long-lasting effects with fewer side effects. Challenges include immune reactions, long-term effects, and high costs.

Asthma drug market focuses on quick-relief and long-term control meds; market driven by asthma prevalence, research advancements, and improved diagnostics; projected to reach $64.6 billion by 2033; major companies include Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sanofi, Pfizer, Teva, and AbbVie.

The AI in Biotechnology Market is projected to grow from USD 2.10 Bn in 2024 to USD 7.11 Bn by 2031, at a CAGR of 19%. Key opportunities include increased diagnostic accuracy, personalized therapies, revolutionized drug discovery, advanced genomic analytics, and integrated healthcare systems. Major players analyzed include AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences Inc.